慢性乙型肝炎患者PD-1/PD-L1信号通路的免疫调节作用研究进展

doi:10.3969/j.issn.1672-5069.2015.06.032

Abstract

Abstract: Programmed cell death-1（PD-1）,as an inhibitory co-stimulatory molecule,is expressed on the surface of T lymphocyte membranes. After interacting with its main ligand,programmed death-1 ligand（PD-L1）,PD-1 decreases immune response of T lymphocytes,and even damages the overall functioning of T lymphocytes. PD-1/PD-L1 signaling pathway plays an important role in the tolerance of T cell immune response triggered by hepatitis B virus infection. Studies indicate that blocking this pathway may provide an new insights into antiretroviral therapy,and might be a promising applications in clinical practice.

Key words: Chronic Hepatitis B, PD-1/PD-L1, T lymphocytes, Immunomodulation

Cao Linlin， Zhang Guoliang.. Immunoregulatory effect of PD-1/PD-L1 signaling pathway in chronic hepatitis B viral infection[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(6): 682-686.

References

[1] Chen GC,Yu T,Huang KH,et al. Antiviral therapy of decompensated hepatitis B virus-related cirrhosis. Chin Med J （Engl）,2012,125（2）:373-377.
[2] Li XD,Wang L,Liu Y,et al. Characterization of hepatitis B virus genotypes/subgenotypes in 1,301 patients with chronic hepatitis B in north China. Chin Med J（Engl）,2011,124（24）:4178-4183.
[3] 聂青和. 转氨酶正常或低于正常值2倍以下慢性乙型肝炎病毒感染者治疗问题. 实用肝脏病杂志,2013,16（4）:293-295.
[4] 解春静. CD4 + CD25 + Tregs在慢性乙型肝炎的发病机制中作用. 中国实用内科杂志,2009,23:126-127.
[5] Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol,2004,4（5）:336-347.
[6] 黄茵. 慢性HBV感染的免疫耐受形成机制. 国外医学流行病学传染病学分册,2001,24（2）：57-60.
[7] 孙克伟,彭建平. 促进细胞免疫学应答-慢性乙型肝炎中医药治疗的机制. 中西医结合肝病杂志,2012,22（4）：193.
[8] 邵崇波. HBV特异性T细胞治疗慢性乙肝的临床研究. 生物磁学,2006,6（1）：87-88.
[9] 张政,王福生.慢性乙型肝炎免疫致病机制和免疫治疗现状.临床肝胆病杂志,2012,28（11）：801.
[10] Kennedy P,Sandalova E,Jo J,et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology,2012,143（3）:637-645.
[11] Schurich A,Khanna P,Lopes AR,et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T cells in persistent hepatitis B virus infection. Hepatology,2011,53 （5）:1494-1503.
[12] Das A,Hoare M,Davies N,et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med,2008,205（9）:2111-2124.
[13] Sandalova E,Laccabue D,Boni C,et al. Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells. Gastroenterology,2012,143 （1）:78-87.
[14] Kakimi K,Guidotti LG,Koezuka Y,et al. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med,2000,192（7）:921-930.
[15] Dunn C,Brunetto M,Reynolds G,et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med,2007,204（3）:667-680.
[16] Zhang Z,Zhang S,Zou Z,et al. Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology,2011,53（1）:73-85.
[17] Topalian SL,Hodi FS,Brahmer JR,et al. Safety,activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med,2012,366（26）:2443-2454.
[18] Brabmer JR,Tykodi SS,Chow LQ,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Eng J Med,2012,366（26）:599-605.
[19] Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med,2012,366（26）:2517-2519.
[20] Ishida Y,Agata Y,Shibahara K,et al. Induced expression of PD-1,a novel member of the immunoglobulin gene superfamily,upon programmed cell death. EMBO J,1992,11（11）:3887-3895.
[21] Okazaki T,Wang J. PD-1/PD-1patliway and autoimmunity. Autoimmunity,2005,38 （5）:353-357.
[22] Okazaki T,Honjo T. PD-1 and PD-1 ligands：from discovery to clinical applications. Int Immunol,2007,19（7）:813-824.
[23] Okazaki T,Maeda A,Nishimura H,et al. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A,2001,98（24）:13866-13871.
[24] 申健,刘芃. PD-1/ PD- L信号通路:研究现况与展望. 现代免疫学,2011,31（4）：335.
[25] Boni C, Fisicaro P,Valdatta C,et a1. Characterization of hepatitis B virus （HBV）-specific T-cell dysfunction in chronic HBV infection. J Virol,2007,81（8）:4215-4225.
[26] Dong H, Zhu G,Tamada K,et a1. B7-H1,a third member of the B7 Family,co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med,1999,5（12）:1365-1369.
[27] 陈俊俊,蒋敬庭,吴昌平. PD-L1信号在免疫应答中的作用及对T细胞的调控机制. 临床检验杂志,2012,30（6）：450.
[28] Fife BT,Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci,2011,1217:45-59.
[29] Margarite L,Tarrio N,Grabie N,et al. PD-1 protects against inflammation and lymphocyte damage in T cell mediated myocarditis. J Immunol,2012,188（10）:4876-4884.
[30] Boettler T,Panther E,Bengsch B,et a1. Expression of the interleukin-7 receptor alpha chai（CD127） on virus-specific CD8 + T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. Virology,2006,80（7）:3532-3540.
[31] Lin DY,Tanaka Y,Iwasaki M,et al. The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci U S A,2008,105（8）: 3011-3016.
[32] Iwai Y,Ishida M,Tanaka Y,et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A,2002,99（19）:12293-12297.
[33] Dulos J,Carven GJ,van Boxtel SJ,et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother,2012,35 （2）:169-178.
[34] 吴介恒,杨安钢,温伟红. PD-1/PD-L1参与肿瘤免疫逃逸的研究进展. 细胞与分子免疫学杂志,2014,13（7）：777-780.
[35] 张美玉,王颖,张雁云. PD-1/PD-L信号通路在免疫调节及免疫相关性疾病中的研究进展. 现代免疫学,2014,22（2）:212-216
[36] Peng G,Li S,Wu W,et al. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol,2008,45（4）:963-970.
[37] 梁雪松,李成忠,万漠彬,等. 外周血T细胞表面PD-1在慢性乙型肝炎患者干扰素治疗期间的表达.世界华人消化杂志,2009,17（28）：2899-2902.
[38] Zhang W J,Peng CH,Zheng SS. Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int,2013,12 （4）:394-399.
[39] Liang XS,Zhou Y,Li CZ,et al. Natural course of chronic hepatitis B is characterized by changing patterns of programmed death typed-1 of CD8-positive T cells. World J Gastroenterol, 2010,16 （5）:618-624.
[40] Zhang Z,Jin B,Zhang JY,et al. Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients. J Hepatol,2009,50（6）:1163-1173.
[41] Ye P,Weng ZH,Zhang SL,et al. Programmed expression is associated with the disease status in hepatitis B virus infection. World J Gastroenterol,2008,14（28）:4551-4557.
[42] Sakuishi K, Apetoh L,Sullivan JM,et a1. Targeting Tim-3 and PD-1 pathway to reverse T cell exhaustion and restore ant-tumor or immunity. J Exp Med,2010,207（10）:2187-2194.
[43] Fisicaro P,Valdatta C,Massari M,et a1. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology, 2010,138（2）:682-693.
[44] 沈立萍,毕胜利. PD-1/PD-L1信号通路与乙肝病毒慢性感染关系的研究进展. 中华实验和临床病毒学杂志,2008,22（6）：513-515.
[45] Boni C,Fisicaro P,Valdatta C,et al. Characterization of hepatitis B virus（HBV）-specific T-cell dysfunction in chronic HBV infection. J Virol,2007,81（8）:4215-4225.
[46] Maier H,Isogawa M,Freeman GJ,et al. PD-1：PD-L1 interactions contribute to the functional suppression of virus-specific CD8 + T lymphocytes in the liver. J Immunol,2007,178 （5）:2714-2720.
[47] Golden-mason L,Palmer B,Karquist J,et al. Up-regulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8 + T cells associated with reversible immune dysfunction. J Virol,2007,81（17）:9249-9258.
[48] Boni C,Fisicaro P,Valdatta C,et al. Characterization of hepatitis B virus（HBV）-specific T-cell dysfunction in chronic HBV infection. J Virol,2007,81（8）:4215-4225.
[49] Isogawa M,Furuichi Y,Chisari FV,et al. Oscillating CD8（+）T cell effector functions after antigen recognition in the liver. Immunity,2005,23（1）:53-63.

Immunoregulatory effect of PD-1/PD-L1 signaling pathway in chronic hepatitis B viral infection

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[3]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[4]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.
[5]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[6]	Wang Baodan, Li Meng, Gao Yu. Predictive factors of response to interferon-α antiviral therapy in children with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 345-348.
[7]	Zhou Jiyun, Ma Yong, Ding Tilong, Tu Yuanhang, Chen Ce. Changes of peripheral blood CD8⁺CD28⁺T lymphocyte percentages in patients with hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 180-183.
[8]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[9]	Wu Jing, Dong Baoji, Wu Chao. Comparison of PD-1 receptor on peripheral blood follicular helper T lymphocyte surface in chronic hepatitis C patients with low and high serum viral loads [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 192-195.
[10]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[11]	Wang Yaofeng.. Efficacy and safety of tenofovir in the treatment of patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 847-850.
[12]	Huang Chunming, Yang Zhan, Nie Yuqiang, et al.. Prediction of liver fibrosis by gamma-glutamyl-transpeptidase-to-platelet ratio in patients with chronic hepatitis B viral infection with normal serum transaminase levels [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 859-862.
[13]	Liu Yingchuan, Zhao Pengcheng, You Ting, et al.. Changes of peripheral blood 25-（OH） 2-D3 levels and peripheral T lymphocyte subsets in patients with primary biliary cirrhosis receiving vitamin D supplementation and ursodeoxycholic acid treatment [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 907-910.
[14]	Baoyan, Wang Yun, Xiang Xiaogang, et al.. Prognosis of patients with hepatocellular carcinoma and underlying hepatitis B An [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 924-927.
[15]	Zhou Sisi, Shen Youxiu, Li Juan, et al.. Changes of peripheral blood Th17 and Treg cells and their related serum cytokines in patients with chronic hepatitis C and liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 689-692.